Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
🏛 National Institutes of Health (HHS-NIH11)
✓ Free, no account · Source: Grants.gov · Last verified Jul 16, 2026
Can you apply?
This grant is for research organizations continuing the EDIC study of type 1 diabetes complications over the long term. Eligible applicants are institutions with established capacity to conduct longitudinal clinical research on diabetes complications and outcomes. The research must focus on the existing EDIC cohort and investigate microvascular disease, cardiovascular outcomes, liver disease, sleep disorders, cognitive decline, and physical function. Applicants must demonstrate expertise in diabetes research, access to study participants, and capability to integrate advanced technologies like continuous glucose monitoring and machine learning approaches.
Not the right fit? Find grants for your organization in 5 questions →
Key dates
- Jan 29, 2026 Applications open
- Jul 1, 2026 Application deadline
- Oct 1, 2026 Award announced
- Jul 1, 2027 Project start
Program description
The primary purpose of this FOA is to support the EDIC Research Center in continuing long-term follow-up of the EDIC cohort to study the development and progression of complications in type 1 diabetes (T1D). The research will address severe microvascular disease, cardiovascular and liver disease, sleep disorders, mortality, and other comorbidities. The goals are to investigate the trajectory of age-related morbidities such as cognition, physical function, and frailty, and to identify their associations with risk factors that affect quality of life, self-management, and caregiver burden. Particular emphasis will be placed on evaluating the impact of emerging therapies, including SGLT2 inhibitors and GLP-1 receptor agonists, on renal and cardiovascular outcomes.
The initiative also encourages the application of advanced statistical methods, including machine learning and artificial intelligence, to identify phenotypes that are either susceptible or resilient to diabetes-related complications. Modern technologies, such as continuous glucose monitoring, coronary calcification imaging, and vascular tonometry, will be used and compared with data from existing cohorts. In addition, the program will support assessments of obesity-related outcomes and comorbidities—including metabolic-associated steatotic liver disease (MASLD) and obstructive sleep apnea (OSA)—within the increasingly overweight/obese T1D population. Multi-omic approaches to identify biochemical signatures associated with complications are also expected. Finally, the leveraging of external databases to examine the cost-effectiveness and quality-of-life impact of intensive therapy across the lifespan will be encouraged.
This is a Forecast for a single source competition that will invite application(s) from eligible organization(s) to apply. Please see Eligibility Section for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.
Who can apply
Eligible applicants
How to apply
Application links
Key dates & requirements
Required documents
- SF-424 (R&R) form
- Project Narrative
- Budget and Budget Justification
- Biosketch (for key personnel)
- Letters of Institutional Support
- Data Management Plan
- Human Subjects Protection documentation
Program contact
- 👤 Division of Diabetes, Endocrinology and Metabolic Diseases
- 📧 NIDDK_DEM@nih.gov
- 📞 NIDDK_DEM@nih.gov
Funding track record
Recent awards under CFDA 93.847 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$438,527,853
-
$200,221,259
-
$152,979,352
-
$112,529,392
-
$66,521,567
-
$45,186,589
-
$39,699,167
-
$37,490,770
-
$34,242,949
-
$31,624,784
Top States by Funding
- WA 3 awards $492.3M
- NC 4 awards $291.6M
- FL 2 awards $184.1M
- MA 6 awards $168.4M
- PA 6 awards $168.1M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.847). How funding has trended year over year.
| 2024 | $1,971,472,000 | |
| 2025 | $2,043,166,000 | |
| 2026 est. | $111,289,000 |
FAQ
Who can apply for this EDIC research center grant?
Research institutions with established diabetes research programs and capacity for long-term cohort follow-up are eligible. Contact the NIH program officer to confirm eligibility before applying.
What is the funding deadline and award timeline?
The deadline is July 1, 2026. Typically, NIH awards are announced 2-3 months after review completion.
What research activities are supported?
The grant funds longitudinal follow-up of type 1 diabetes patients, investigating complications like kidney disease, heart disease, liver disease, sleep disorders, and cognitive decline. Studies of emerging therapies like SGLT2 inhibitors and GLP-1 agonists are encouraged.
How competitive is this grant?
This is a single-source cooperative agreement, highly competitive and merit-reviewed. Strong preliminary data, experienced research teams, and alignment with NIH priorities strengthen applications.
What is the typical award amount?
Award amounts for NIH U01 cooperative agreements vary; contact the NIH program officer for specific guidance on this FOA's funding range.
💡 Tips for applicants
- Emphasize your institution's track record maintaining long-term cohort engagement and data quality in diabetes research.
- Highlight how emerging technologies (continuous glucose monitoring, AI/machine learning) will advance the research and generate new insights.
- Clearly describe partnerships with other institutions or data sources that strengthen the study's scientific scope and generalizability.
- Address the three priority areas: complications in aging, impact of new therapies, and obesity-related comorbidities in type 1 diabetes.
- Develop a detailed budget narrative explaining how funds support participant follow-up, data collection infrastructure, and advanced analytical methods.
⚠️ Common mistakes
Failing to demonstrate existing relationships with the EDIC cohort or institutional capacity for long-term participant retention. Proposing research activities outside the diabetes complications focus or applying without established expertise in longitudinal clinical research. Underestimating the budget and timeline needed for sustained cohort follow-up, technology integration, and multi-omic analyses.
Similar grants
- OPEN Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Single Source Competition: Continuation of the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D) – Resource Center (U24 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Diabetes Research Centers (P30 Clinical Trial Optional) — National Institutes of Health
- CLOSED Single Source for Establishing Pilot/Opportunity program for AI Models to Accelerate Diabetes Research (U24- Clinical Trials not allowed) — National Institutes of Health
- CLOSED Notice of Intent to Publish a Funding Opportunity Announcement for Single Source for Continuation of the Environmental Determinants of Diabetes in The Young Study (TEDDY) Data Coordinating Center (U01 — National Institutes of Health